The next two webinars in the public health series address (1) the sound science behind the rapid COVID vaccine development and (2) how to communicate that to underserved communities. Register for both webinars below. See the OMH grant notice.
COVID inoculation rates in U.S. minority communities are dismal, hovering around 8%. They are currently eight times higher in white communities. Studies show that causes include misinformation about vaccine effectiveness and safety, lack of trust in government institutions and drug companies, the digital divide, language barriers, inaccessibility of vaccination sites, deportation fears by undocumented immigrants, identifying and reaching underserved communities to address equity, among others.

Join the American Public Health Association, the GWU Milken Institute School of Public Health, MDB, and SSF, in a free 90-minute webinar explaining tools and approaches to raise vaccination rates in underserved communities. Panelists from

  • Office of the Assistant Secretary for Preparedness and Response and the Office of Minority Health in the Department of Health and Human Services providing the latest tools, technical assistance, and grants for addressing equity and reaching underserved communities.
  • Social, Economic, and Housing Statistics Division of the Census Bureau demonstrating the Community Resilience Estimates (CRE) program that uses granular data to measure individuals and community capacity to respond to the COVID-19 Pandemic.
  • Local healthcare official on the frontlines of healthcare equity.

More about the panel shortly.
April 1, 2021
1:15 PM to 2:45 PM EST
Register if you can't make it and get the recording link.
Alert colleagues.
Fortunately, COVID vaccines have been developing at a record pace. How has that been done, were any testing corners cut, safety standards violated and vaccines rushed into the public domain?

In the second Public Health webinar in this series, the American Public Health Association, the GWU Milken Institute School of Public Health, MDB and SSF, will convene vaccine research, manufacturing, and regulatory experts to answer these questions and provide you with important insights into the science and engineering behind vaccinology and implications for addressing new viruses and variants.

Meet the Panelists From - Moderna, the Coalition for Epidemic Preparedness Innovations, and former FDA and Sanofi-Pasteur officials.
Moderator: Alan Liss is the Founder of GXP farma, LLC, which provides strategic mentoring and consulting, including auditing, compliance programs & regulatory strategy development for successful interactions with global regulatory agencies for biotech and pharmaceutical companies. He is a subject matter expert for project management and drug and biologics development and regulatory approval. Formally Alan was the Director of MCMI PHSAT (medical countermeasures) at US FDA, Office of Counterterrorism and Emerging Threats, and former Deputy Director of the Regulatory and Quality Affairs Group in Biomedical Advanced Research and Development Authority in HHS
Wellington Sun is a Senior Consultant, Vaxcellerant LLC and the former Head of Vaccine Strategy and Regulatory Affairs at Moderna Therapeutics. Dr. Sun came to Moderna from the U.S. Food and Drug Administration (FDA), where he was Director of the Division of Vaccines and Related Product Applications at the Center for Biologics Evaluation and Research (CBER). He is an infectious disease physician-scientist with diverse expertise in medicine, science, clinical research, and FDA regulation of infectious disease vaccines and other biotherapeutics.
Amy Shertleff holds a Ph.D. in Viral Pathogenesis and is a Senior Scientist in Preclinical Models at the Coalition for Epidemic Preparedness Innovations (CEPI), where she administers research programs for vaccine testing in preclinical infection models. She has served as the lead research investigator and study director for programs testing DNA vaccines, the Ebola vaccine ERVEBO, and other novel vaccine platforms through a long tenure at the United States Army Research Institute for Infectious Diseases. She has also served as an annual instructor in the UTMB/FDA joint course ‘Achieving Data Quality and Integrity in Maximum Containment Laboratories’. She has 20 years of hands-on experience in the design, development, and preclinical testing of antiviral vaccines and therapeutics under high biocontainment with pathogens such as influenza, arenaviruses, hantaviruses, ebolaviruses, and coronaviruses.
Raafat Fahim holds a Ph.D in Biochemistry and is the President of REFF Consulting. He has 35 years of experience in the Vaccines, Biologics, and Biotechnology industries. He is currently consulting for several organizations including the Coalition for Epidemic Preparedness Innovations (CEPI) where he is a Senior Vaccines Development and manufacturing consultant. Previously, he was the President and Chief Executive of Nabi Pharmaceuticals, a Biopharmaceutical Company specialized in Vaccines and Plasma products.   Prior to joining Nabi Biopharmaceuticals, Dr. Fahim was the Vice President of late-stage Development and Manufacturing at Sanofi-Pasteur where he was instrumental in developing several essential vaccines from early research to regulatory approval and commercialization
Remaining ASU Sustainability Solutions Festival Webinars
Edward Saltzberg
Sincerely,

Ed.

Edward Saltzberg, PhD
Executive Director
Security and Sustainability Forum